Request Demo

Last update 08 May 2025

Colorado Center of Orthopaedic Excellence, Inc.

Private Company|2007|Colorado, United States|

50-100

ccoe.us

Private Company|2007|Colorado, United States|

50-100

ccoe.us

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Colorado Center of Orthopaedic Excellence, Inc.

0 Patents (Medical) associated with Colorado Center of Orthopaedic Excellence, Inc.

Literatures (Medical) associated with Colorado Center of Orthopaedic Excellence, Inc.

01 Apr 2025·Journal of Shoulder and Elbow Surgery

Impact of Insurance and Implant Coverage on Arthroscopic Shoulder Surgery Patients: A Prospective Multicenter Analysis

Article

Author: Port, Joshua ; Abdelshahed, Mina ; Hill, Brian W ; Weinstein, David ; Jarrett, Claudius D ; Maali, Raed ; Bushnell, Brandon D ; Cil, Akin ; Wright, Melissa A ; Khan, Adam Z

BACKGROUNDAdvances in implant technology for arthroscopic shoulder surgery allow patients to achieve similar success rates as traditional approaches with reduced morbidity and quicker recovery. However, in the U. S. healthcare system, insurance coverage for these implants remains variable. Unlike commercial carriers, patients with governmental insurance typically do not have coverage for arthroscopic shoulder implants. How this disparity impacts the healthcare of patients with shoulder pathology remains unclear.METHODSWe performed a prospective multicenter study analyzing the effects of insurance type and implant coverage on patients undergoing arthroscopic shoulder surgery. Patients were selected upon confirmation of surgery. Each case was documented for patient age, American Society of Anesthesiologists (ASA) score, body mass index (BMI), race, and sex. Each case was then categorized based on insurance carrier (traditional Medicare, managed Medicare, commercial plans, Medicaid, workers' compensation, cash, or other governmental insurance). The timing for surgery, primary surgical indication, whether a primary or revision surgery, number of anchors used, site of service (freestanding Ambulatory Surgery Centers (ASCs) versus hospital-based operating room), and utilization of biologic or structural grafts were all then tracked.RESULTSA total of 326 cases from six participating states were analyzed. In comparison to ASCs, patients having surgery in hospital settings were older (56.8 vs. 52.0 years), had a higher Body Mass Index (BMI) (31.3 vs. 29.0), had higher ASA scores (2.4 vs. 1.9), and were more likely to be non-white (41.2% vs 31.5%). (p<0.05) After controlling for comorbidities, patients with Medicare Advantage (71%), Traditional Medicare (55%), and Medicaid/Cash (66%) were more likely to have their surgery in the hospital setting than patients with commercial plans (42%) (p<0.05). Hospital patients waited significantly longer before surgery in comparison to ASC patients (45.9 days vs. 34.4 days) (p<0.05). No statistically significant difference was identified between the number of anchors used and the insurance carrier (p = 0.58). A higher percentage of surgeries in the hospital (19.6%) included biologics versus those in an ASC (10.4%) (p = 0.03).CONCLUSIONPatients with governmental insurance plans were less likely to undergo arthroscopic shoulder surgery at an ASC than at a hospital-based facility. Patients who had their surgery at a hospital facility had a longer wait until surgery. Insurance carrier and implant coverage might influence where and when a patient receives care. Equal coverage of surgical implants for arthroscopic shoulder surgery would improve timely access and care for shoulder pathology. Legislatures should closely consider these findings when developing insurance policies.

27 Mar 2025·Journal of Hip Preservation Surgery

EP1.12 Revision Arthroscopic Labral Reconstruction: Pushing the Science of Hip Preservation Surgery

Author: White, Brian ; Constantinides, Shannon

AbstractPurpose: Patients who have experienced failure of arthroscopic labral reconstruction of the hip have traditionally been left with limited options, such as living with pain and dysfunction, or undergoing hip arthroplasty. The purpose of our study was to evaluate the outcomes of revision arthroscopic circumferential allograft labral reconstruction (CLR) in nonarthritic hips which had previously undergone labral reconstruction by the same surgeon.Method: Data from 24 hips (∼ 1% of the lead author’s surgical panel during a 4-year collection period) were evaluated to determine the efficacy of revision CLR based on validated patient-reported outcomes.Results: The success rate of the operation was 96%. PROs demonstrated statistically significant improvement with strong measures of effect. Modified Hip Harris Scores (mHHS) improved by a mean of 26.68 points. 88% of patients met the minimal clinically important difference (MCID) for mHHS (+6.49, p < .001, d = 1.32), and the majority of these patients met the patient acceptable symptom state (PASS) threshold. Lower Extremity Functional Scale (LEFS) scores improved by a mean of 21.88 points. 78% of patients met the MCID (+7.79, p < .001, d = 1.32) for LEFS.Conclusion: While labral reconstruction has broadly been shown to result in highly favorable outcomes, our study demonstrated that in the rare case of failure, revision CLR is not only feasible, but results in improved pain and functionality.

31 Dec 2024·Journal of Hip Preservation Surgery

Failed labral reconstruction of the hip can be successfully revised to another labral reconstruction: improved patient-reported outcomes at a minimum of 2-year follow-up

Article

Author: Constantinides, Shannon M ; White, Brian J ; Shafer, Anna ; Spears, Hannah ; Swann, R. Presley

AbstractThe purpose of this study was to validate the success of revision arthroscopic circumferential allograft labral reconstruction (CLR) in nonarthritic hips, which, in the rare case of failure, had previously undergone labral reconstruction by the same surgeon. Using a minimum of 24-month follow-up, data from 24 hips having undergone revision CLR were analyzed to determine improvements in patient-reported outcomes (PROs). All included cases completed a minimum of 24 months follow-up, with a success rate of 96%. All PROs improved significantly, with exceptionally strong measures of effect. Modified Harris Hip Scores improved by a mean of 26.68 points, with 88% of patients meeting the minimal clinically important difference (MCID) (+6.49, P ≤ .001, d = 1.32). Lower Extremity Functional Scale scores improved by a mean of 21.88 points, with 78% of patients meeting the MCID (+7.79, P ≤ .001, d = 1.32). Pain as rated by the Visual Analog Scale, including at rest, during activities of daily living, and with sports, was significantly improved with strong measures of effect, with >75% of patients having met the MCID. This study validated that a failed labral reconstruction of the hip can be revised safely and effectively to another labral reconstruction of the hip. While labral reconstruction has broadly been shown to result in highly favorable outcomes, this study demonstrated that in the rare case of failure, revision CLR is not only feasible but results in improved pain and functionality.

100 Deals associated with Colorado Center of Orthopaedic Excellence, Inc.

100 Translational Medicine associated with Colorado Center of Orthopaedic Excellence, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colorado Center of Orthopaedic Excellence, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 07 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing